VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
VTS-Platform
Aspirin is one of the oldest, most complex drugs in medicine, with many different indications and applications. It has unique pharmacokinetic properties where its metabolites effect aspirin itself, depending on the rates of metabolism in different parts of the body.
Aspirin has been used to reduce the Niacin Flush (and Fumarate Flush) for decades, but it only would work as a pretreatment: patients would have to take it at least 30 minutes before the main drug, several times a day, every day – something very few patients will do.
We have discovered a new unique formulation of aspirin that aims to enhance both its pharmacokinetics and
flush reduction ability, allowing for simultaneous ingestion – and therefore combination into one medication.